T. Muley
About
In The Last Decade
T. Muley
16 papers receiving 426 citations
Peers
Comparison fields: 5 of 63
- Oncology 280
- Pulmonary and Respiratory Medicine 186
- Molecular Biology 161
- Cancer Research 72
- Radiology, Nuclear Medicine and Imaging 62
Countries citing papers authored by T. Muley
This map shows the geographic impact of T. Muley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Muley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Muley more than expected).
Fields of papers citing papers by T. Muley
This network shows the impact of papers produced by T. Muley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Muley. The network helps show where T. Muley may publish in the future.
Co-authorship network of co-authors of T. Muley
This figure shows the co-authorship network connecting the top 25 collaborators of T. Muley. A scholar is included among the top collaborators of T. Muley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Muley. T. Muley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 2 | |
| 3 | 1 | |
| 4 | 2 | |
| 5 | 24 | |
| 6 | Expression of thymidylate synthase (TYMS) and Insulin growth factor 1 (IGF1) in completely-resected NSCLC patients: associations with histological subtype and prognosis | 1 |
| 7 | 20 | |
| 8 | 27 | |
| 9 | [Clinical and prognostic significance of tumor markers cytokeratin 19 fragment, carcinoembryonic antigen, and neuron-specific enolase in lung cancer]. | 0 |
| 10 | 164 | |
| 11 | Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. | 58 |
| 12 | CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy. | 20 |
| 13 | [Lung metastases: tumor reduction as an oncologic concept]. | 2 |
| 14 | [Treatment strategy in pleural mesothelioma]. | 0 |
| 15 | Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE. | 32 |
| 16 | 1 | |
| 17 | 31 | |
| 18 | 5 | |
| 19 | 42 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.